The clinical triad of pyoderma gangrenosum (PG), acne and suppurative hidradenitis (PASH) has recently been described as a new disease entity within the spectrum of autoinflammatory syndromes, which are an emerging group of inflammatory diseases distinct from autoimmune, allergic and infectious disorders. PASH syndrome is similar to PAPA (pyogenic arthritis, acne and PG), but it differs in lacking the associated arthritis and on a genetic basis. PAPA syndrome is caused by mutations in a gene involved in the regulation of innate immune responses, the PSTPIP1, while no mutations have been detected to date in patients with PASH syndrome. We report a young male patient who developed coexisting disseminated PG, typical suppurative hidradenitis and acneiform eruption on the face, after he had undergone bowel bypass surgery for obesity. The cutaneous manifestations associated with bowel bypass syndrome often mimic PG or other neutrophilic dermatoses, suggesting a pathogenesis related to neutrophil-mediated inflammation for this condition. This is the first report describing PASH syndrome after bariatric surgery, and we propose to include such neutrophilic dermatoses in the list of complications occurring after bowel bypass surgery. Extensive genetic studies may help to clarify the etiopathogenesis of PASH as well as of autoinflammatory diseases in general.

Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T: Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) – a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol 2012;66:409–415.
Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, Bashiardes S, Lovett M: Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet 2002;11:961–969.
Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A: Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey: 85 cases. Rev Rhum Mal Osteoartic 1987;54:187–196.
Chen W, Obermayer-Pietsch B, Hong JB, Melnik BC, Yamasaki O, Dessinioti C, Ju Q, Liakou AI, Al-Khuzaei S, Katsambas A, Ring J, Zouboulis CC: Acne-associated syndromes: models for better understanding of acne pathogenesis. J Eur Acad Dermatol Venereol 2011;25:637–646.
André MF, Aumaître O, Grateau G, Chamaillard M, Costedoat-Chalumeau N, Cardoso MC, Henry-Berger J, Ramakrishna BS, Delpech M, Piette JC, Creveaux I: Longest form of CCTG microsatellite repeat in the promoter of the CD2BP1/PSTPIP1 gene is associated with aseptic abscesses and with Crohn disease in French patients. Dig Dis Sci 2010;55:1681–1688.
Hsiao JL, Antaya RJ, Berger T, Maurer T, Shinkai K, Leslie KS: Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol 2010;146:1265–1270.
Ah-Weng A, Langtry JA, Velangi S, Evans CD, Douglas WS: Pyoderma gangrenosum associated with hidradenitis suppurativa. Clin Exp Dermatol 2005;30:669–671.
Callen JP: Neutrophilic dermatoses. Dermatol Clin 2002;20:409–419.
Shagrin JW, Frame B, Duncan H: Polyarthritis in obese patients with intestinal bypass. Ann Intern Med 1971;75:377–380.
Cantatore FP, Carrozzo M, Loperfido MC: Post biliopancreatic bypass arthritis: dermatitis syndrome. Clin Rheumatol 1991;10:449–451.
Delaney TA, Clay CD, Randell PL: The bowel-associated dermatosis–arthritis syndrome. Australas J Dermatol 1989;30:23–27.
Brouard MC, Chavaz P, Borradori L: Acute pustulosis of the legs in diverticulitis with sigmoid stenosis: an overlap between bowel-associated dermatosis-arthritis syndrome and pustular pyoderma gangrenosum. J Eur Acad Dermatol Venereol 2004;18:89–92.
Poli F, Wolkenstein P, Revuz J: Back and face involvement in hidradenitis suppurativa. Dermatology 2010;221:137–141.
Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA: Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010;62:205–217.
Brooklyn TN, Dunnill MGS, Shetty A, Bowden JJ, Williams JDL, Griffiths CEM, Forbes A, Greenwood R, Probert CS: Infliximab for the treatment of pyoderma gangrenosum: a randomised, double bind, placebo controlled trial. Gut 2006;55:505–509.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.